Mark Kowala

Mark Kowala is currently serving as the VP Translational Medicine at Indiana Biosciences Research Institute since December 2021. Prior to this role, Mark held the position of Chief Scientific Officer at Eli Lilly and Company from June 2007 to April 2021. Mark has a B.Sc. (Hons) in Immunology from Monash University and a Ph.D. in Pathology/Experimental Pathology from The Australian National University. During their time at Eli Lilly, Mark reorganized and rebuilt a team of scientists, defined strategic goals, and executed projects that resulted in a robust cardiovascular portfolio with assets now in clinical development, utilizing various therapeutic modalities such as small molecules, peptides, mabs, and siRNA.